Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.
Brodtkorb TH, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.
Mullins CD, Earnshaw SR, Brodtkorb T-H. Budget impact analysis I - A 6-step approach. Presented at the 2020 ISPOR Virtual Conference; June 18, 2020.
Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700
Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. The budget impact of introducing tildrakizumab to a United States health plan for managing moderate-to-severe plaque psoriasis. Pharmacoeconomics. 2020 Mar 26.